Clinical Trial

Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated June 30, 2026 (before its estimated July 11, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the study is to evaluate the pharmacokinetics (PK) of Suzetrigine (SUZ) and its metabolite in the absence and presence of efavirenz, a moderate CYP3A inducer. In addition, the purpose is to evaluate the safety and tolerability of SUZ when administered in the absence and presence of efavirenz.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-01
critical Recruitment opened 2026-06-03
Trial Details
NCT Number NCT07570069
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Pain
Enrollment 18 participants
Start Date 2026-05-07
Primary Completion 2026-07-11 (estimated)
Study Completion 2026-07-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-30